| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/05/2024 | 22:05 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 04/05/2024 | 02:59 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 16/04/2024 | 13:00 | GlobeNewswire Inc. | Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 10/04/2024 | 14:00 | GlobeNewswire Inc. | Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 09/04/2024 | 14:00 | GlobeNewswire Inc. | Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 27/02/2024 | 13:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 14/11/2023 | 22:30 | GlobeNewswire Inc. | Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 07/11/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 23/10/2023 | 14:30 | GlobeNewswire Inc. | Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 27/09/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 08/09/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 01/09/2023 | 22:15 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 17/08/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 15/08/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 14/08/2023 | 22:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 01/08/2023 | 14:30 | GlobeNewswire Inc. | Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 24/07/2023 | 14:15 | GlobeNewswire Inc. | Qualigen Therapeutics Divests FastPack® Diagnostics Business | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 07/07/2023 | 23:08 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 26/06/2023 | 23:25 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 13/06/2023 | 23:16 | Edgar (US Regulatory) | Securities Registration Statement (s-1) | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 05/06/2023 | 14:15 | GlobeNewswire Inc. | Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 02/06/2023 | 22:11 | Edgar (US Regulatory) | Annual Report to Security Holders (ars) | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 16/05/2023 | 14:00 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 15/05/2023 | 23:14 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 02/05/2023 | 22:30 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 02/05/2023 | 14:15 | GlobeNewswire Inc. | Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 21/04/2023 | 23:46 | GlobeNewswire Inc. | Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 18/04/2023 | 14:45 | GlobeNewswire Inc. | Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 18/04/2023 | 13:30 | GlobeNewswire Inc. | Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL | NASDAQ:QLGN | Qualigen Therapeutics Inc |
| 31/03/2023 | 22:09 | Edgar (US Regulatory) | Notification That Annual Report Will Be Submitted Late (nt 10-k) | NASDAQ:QLGN | Qualigen Therapeutics Inc |